Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients

1. Margusino-Framiñán, L.
2. Cid-Silva, P.
3. Rotea-Salvo, S.
4. Mena-De-Cea, Á.
5. Suárez-López, F.
6. Vázquez-Rodríguez, P.
7. Delgado-Blanco, M.
8. Sanclaudio-Luhia, A.I.
9. Martín-Herranz, I.
10. Castro-Iglesias, Á.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1136/EJHPHARM-2019-002060 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus